- Investing.com
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Metrics to compare | OMER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMERPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −1.2x | −0.5x | |
PEG Ratio | 0.03 | 0.00 | 0.00 | |
Price / Book | −0.9x | 0.2x | 2.6x | |
Price / LTM Sales | - | 4.8x | 3.1x | |
Upside (Analyst Target) | - | 193.5% | 50.4% | |
Fair Value Upside | Unlock | 16.3% | 8.7% | Unlock |